53013-41-5Relevant articles and documents
Discovery of novel FMS kinase inhibitors as anti-inflammatory agents
Illig, Carl R.,Chen, Jinsheng,Wall, Mark J.,Wilson, Kenneth J.,Ballentine, Shelley K.,Rudolph, M. Jonathan,DesJarlais, Renee L.,Chen, Yanmin,Schubert, Carsten,Petrounia, Ioanna,Crysler, Carl S.,Molloy, Christopher J.,Chaikin, Margery A.,Manthey, Carl L.,Player, Mark R.,Tomczuk, Bruce E.,Meegalla, Sanath K.
, p. 1642 - 1648 (2008/12/22)
The optimization of the arylamide lead 2 resulted in identification of a highly potent series of 2,4-disubstituted arylamides. Compound 8 (FMS kinase IC50 = 0.0008 μM) served as a proof-of-concept candidate in a collagen-induced model of arthri
AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE
-
Page/Page column 68-69, (2008/06/13)
The invention relates to compounds of Formula (I), wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.
Regular trends in nucleophilic substitutions in 2-alkylamino-4- chloronitrobenzenes
Zotova,Kushakova,Kuznetsov,Rodin,Garabadzhiu
, p. 214 - 217 (2007/10/03)
The effect of substituents in position 2 on the reactivity of 2-alkylamino-4-chloronitrobenzenes in nucleophilic substitution by N-nucleophiles of various character was studied. 2005 Pleiades Publishing, Inc.
